SS-31 (Elamipretide) · Research brief

SS-31 Research Log Track Document — Lab Protocol Guide

Real Peptides Research TeamEditorial

Updated May 5, 20269 min read

60 WORDS

Short answer

Most SS-31 research failures aren't peptide quality issues. They're documentation failures. A study published in Nature Methods found that 70% of mitochondrial peptide research inconsistencies traced back to inadequate storage and handling logs, not compound degradation. Without a structured SS-31 research log track document system, temperature excursions go unrecorded, reconstitution timing gets lost, and six months of work becomes unreproducible.…

Key takeaways

SS-31 lyophilized powder must be stored at −20°C minimum (−80°C preferred) with twice-daily temperature logging to detect freezer failures before peptide degrades.
Reconstituted SS-31 remains stable for 28 days maximum at 2–8°C. The stability clock starts at reconstitution, not first use, and exceeding this window risks bacterial contamination even with bacteriostatic water.
Every freeze-thaw cycle reduces peptide bioactivity incrementally; aliquot SS-31 into single-use volumes immediately upon reconstitution and never refreeze thawed peptide.
pH drift below 6.0 or above 7.5 accelerates SS-31 aggregation. Include pH verification in your documentation at reconstitution and midpoint if the vial remains in use beyond 14 days.
Regulatory audits reject studies not for protocol deviations but for failure to document them. Your SS-31 research log track document must include a deviation log with timestamps, corrective actions, and investigator signatures.

Most SS-31 research failures aren't peptide quality issues. They're documentation failures. A study published in Nature Methods found that 70% of mitochondrial peptide research inconsistencies traced back to inadequate storage and handling logs, not compound degradation. Without a structured SS-31 research log track document system, temperature excursions go unrecorded, reconstitution timing gets lost, and six months of work becomes unreproducible.

Our team has worked with research facilities running SS-31 (elamipretide) protocols for cardioprotection, neuroprotection, and mitochondrial dysfunction studies. The gap between publishable results and wasted batches comes down to one thing: whether your lab treats documentation as a compliance checkbox or a research integrity tool.

What is an SS-31 research log track document?

An SS-31 research log track document is a standardized record-keeping system that tracks peptide storage conditions, reconstitution protocols, administration timing, and environmental variables throughout the research lifecycle. It captures lyophilized storage temperatures (typically −20°C to −80°C), reconstitution timestamps with specific diluent volumes, post-reconstitution refrigeration compliance (2–8°C), and any temperature excursions that could denature the peptide's tertiary structure. These logs serve as both chain-of-custody verification and troubleshooting tools when results don't replicate.

Here's what most protocols miss: SS-31 isn't just a peptide you mix and inject. It's a mitochondria-targeting tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) with a lipophilic cation that accumulates 1000-fold in mitochondrial inner membranes. The compound's therapeutic mechanism. Cardiolipin stabilization and cytochrome c retention. Depends entirely on preserving that aromatic-cationic motif through every handling step. Temperature logs aren't bureaucracy. They're the difference between studying an active compound and studying degraded fragments. This article covers the core documentation framework every SS-31 lab needs, the storage variables that matter most, and the tracking gaps that institutional audits consistently flag.

Critical Documentation Points in SS-31 Research Protocols

Every SS-31 research log track document must capture five non-negotiable data points: receipt timestamp with manufacturer lot verification, lyophilized storage temperature with twice-daily monitoring, reconstitution date with specific bacteriostatic water volume used, post-reconstitution refrigeration compliance, and any deviations or temperature excursions with corrective actions taken. These aren't administrative formalities. They're the mechanistic anchors that let you trace unexpected results back to handling variables.

SS-31 arrives as a lyophilized powder requiring storage at −20°C minimum, though −80°C extends stability significantly. The peptide's Dmt (dimethyltyrosine) residue is particularly vulnerable to oxidative degradation above freezing. Even 24 hours at room temperature can reduce bioactivity by 15–20% based on HPLC assay data from supplier certificates of analysis. Your log must record not just the set temperature but actual measured temperature twice daily, because freezer malfunctions are the single most common cause of batch loss in mitochondrial peptide research.

Reconstitution protocol documentation separates reproducible studies from guesswork. Record the exact diluent type (bacteriostatic water with 0.9% benzyl alcohol is standard), volume added (typically 1–2mL for 5mg vials to achieve 2.5–5mg/mL concentration), and mixing method (gentle swirling, never vortexing. Mechanical shear denatures peptide bonds). Once reconstituted, SS-31 must be refrigerated at 2–8°C and used within 28 days maximum. The clock starts at reconstitution, not first use. This timing matters because bacteriostatic preservatives lose effectiveness after four weeks even under ideal conditions.

We've reviewed logs from facilities that lost entire study cohorts because they logged 'refrigerated' without specifying whether that meant 4°C or 10°C. SS-31 stability drops measurably above 8°C. Precision matters. Your SS-31 research log track document should include a deviation log with temperature excursion thresholds: any reading above −15°C for lyophilized storage or above 10°C for reconstituted peptide triggers a mandatory review and potential batch discard decision.

SS-31 Research Log Track Document: Storage and Handling Variables

The variables that most impact SS-31 integrity. And therefore must be tracked rigorously. Fall into three categories: thermal management, light exposure, and pH stability post-reconstitution. Institutional review boards and journal editors increasingly demand this granular documentation, especially for studies claiming neuroprotective or cardioprotective outcomes where dosing precision determines whether effects are real or artifacts.

Thermal cycling is the silent killer of mitochondrial peptides. Every freeze-thaw cycle degrades peptide structure incrementally. Opening a −80°C freezer for 30 seconds raises internal vial temperature by 2–5°C depending on placement. Best practice: aliquot SS-31 immediately upon reconstitution into single-use volumes (typically 100–200μL per tube), freeze at −80°C, and thaw each aliquot exactly once. Your log should track aliquot ID, freeze date, thaw date, and whether that aliquot was discarded after use or refrozen (spoiler: never refreeze).

Light exposure accelerates oxidation of aromatic residues, particularly the Dmt that gives SS-31 its mitochondrial selectivity. Store vials in amber glass or wrap them in foil. And log it. Ambient lab lighting at 500 lux for eight hours can reduce SS-31 potency by 8–12%. This isn't theoretical: a 2019 study in Biochimica et Biophysica Acta demonstrated photodegradation of cardiolipin-binding peptides under standard fluorescent lighting.

PH documentation matters more than most protocols acknowledge. Bacteriostatic water typically has a pH of 5.0–7.0, and SS-31 shows maximum stability at pH 6.5–7.0. If your reconstitution diluent sits outside that range, peptide aggregation accelerates. Include pH measurement in your SS-31 research log track document immediately post-reconstitution and again at day 14 if the vial remains in use. Any drift below 6.0 or above 7.5 should trigger batch replacement.

Chain-of-Custody and Compliance Tracking

Regulatory audits and IRB reviews consistently flag inadequate chain-of-custody documentation for research-grade peptides. An SS-31 research log track document isn't optional if your work will be submitted to peer review or used to support investigational new drug (IND) applications. The FDA's Good Laboratory Practice (GLP) standards. Specifically 21 CFR Part 58. Require written records demonstrating peptide identity, purity, and stability throughout the study period.

Your log must include: manufacturer certificate of analysis (CoA) with HPLC purity verification (SS-31 should be ≥98% pure), receipt inspection confirming vial integrity and proper shipping temperature (dry ice shipment should arrive at ≤−70°C), and storage transfer records if peptide moves between freezers or facilities. Each transfer requires signature, timestamp, and temperature verification at both origin and destination.

Deviation tracking is where most labs fail audits. Every instance where protocol wasn't followed perfectly. Freezer alarm triggered, reconstituted vial left at room temp for 45 minutes, aliquot dropped and discarded. Must be logged with corrective action taken. We mean this sincerely: institutional review boards reject studies not because deviations happened, but because researchers didn't document them. Transparency beats perfection every time in research integrity assessments.

Real Peptides maintains detailed handling protocols for every peptide in their catalog, including storage temperature ranges, reconstitution best practices, and stability data under various conditions. Their technical documentation can serve as a reference standard when building your own SS-31 research log track document framework. Particularly the stability timelines for mitochondrial-targeting peptides.

SS-31 Research Log Track Document: Comparison of Methods

What If: SS-31 Documentation Scenarios

What If the Freezer Alarm Triggered Overnight?

Document the exact duration of the temperature excursion, the maximum temperature reached, and whether vials were relocated to a backup freezer. If lyophilized SS-31 remained below 0°C, stability is likely preserved. HPLC assay the batch if possible or proceed with heightened caution and flag the event in your study notes. If temperature exceeded 0°C for more than two hours, discard the batch. SS-31's Dmt residue begins oxidizing rapidly above freezing, and there's no reliable way to verify full potency without mass spectrometry.

What If Reconstituted SS-31 Was Left at Room Temperature for Three Hours?

Log the incident immediately with exact time out of refrigeration. SS-31 tolerates brief ambient exposure (15–30 minutes during aliquoting), but three hours at 20–25°C represents significant risk. The peptide's cardiolipin-binding mechanism depends on preserving the aromatic-cationic motif, which denatures progressively above 8°C. If this was a single-use aliquot and you proceed with administration, note the exposure in your dose log and flag any unexpected results. You may be studying a partially degraded compound.

What If the Reconstitution Date Wasn't Logged?

This is a hard failure for regulatory compliance. Without a documented reconstitution timestamp, you cannot verify the 28-day sterility window. If the vial is still in use and you estimate it's been fewer than 14 days since mixing, you can salvage it by logging current date, estimating reconstitution date conservatively, and discarding the vial at 28 days from your best estimate. If you have no confidence in timing, discard the vial and implement a mandatory immediate-logging protocol for all future reconstitutions.

The Unflinching Truth About SS-31 Documentation

Here's the honest answer: most SS-31 studies that fail to replicate aren't failing because of biological variability or species differences. They're failing because researchers treated documentation as a compliance checkbox instead of a research tool. Temperature excursions that degraded peptide potency by 20% never made it into the methods section. Reconstitution volumes were 'approximately 1mL' instead of precisely measured. And when results didn't match pilot data, investigators had no handling log to review.

A properly maintained SS-31 research log track document isn't extra work. It's the only way to know whether you're studying the compound you think you're studying. Mitochondrial-targeting peptides are exquisitely sensitive to storage and handling conditions. The difference between a cardioprotective effect and a null result can be a single freeze-thaw cycle you didn't document. Journals are rejecting more papers every year for inadequate methodology transparency, and 'we stored peptide according to manufacturer instructions' no longer meets peer review standards when you're claiming neuroprotective mechanisms.

If your current system can't tell you. Right now, without searching. The exact temperature history of every SS-31 vial in your freezer, you don't have a documentation system. You have a liability. Fix it before your next study cohort, not after results come back inconsistent.

Managing research-grade peptides requires infrastructure and commitment that goes beyond purchasing high-purity compounds. The documentation framework matters as much as the peptide itself. One verifies the other. When results depend on preserving molecular structure through every handling step, tracking those steps isn't optional.

References

Peer-reviewed sources on SS-31 (Elamipretide) indexed in PubMed, listed for research context. Real Peptides supplies SS-31 (Elamipretide) for laboratory research use only.

Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International journal of molecular sciences, 2025. PMID 39940712. doi:10.3390/ijms26030944
Elamipretide: First Approval. Drugs, 2026. PMID 41335372. doi:10.1007/s40265-025-02269-8
SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. PMID 41136322. doi:10.1016/j.neurot.2025.e00772
SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 39848110. doi:10.1016/j.biopha.2025.117832
Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 40294492. doi:10.1016/j.biopha.2025.118056
SS-31 Targets NOS2 to Enhance Osteogenic Differentiation in Aged BMSCs by Restoring Mitochondrial Function. Organogenesis, 2025. PMID 40570323. doi:10.1080/15476278.2025.2519649
Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31. Journal of the American Society of Nephrology : JASN, 2024. PMID 38530359. doi:10.1681/ASN.0000000000000338
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in medicine : official journal of the American College of Medical Genetics, 2024. PMID 38602181. doi:10.1016/j.gim.2024.101138

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Lyophilized SS-31 stored at −20°C maintains stability for 12–24 months from manufacture date, while storage at −80°C can extend this to 36 months based on manufacturer stability data. The critical factor is avoiding temperature fluctuations above −15°C — each excursion accelerates oxidative degradation of the Dmt residue that gives SS-31 its mitochondrial selectivity. Always verify the expiration date on the certificate of analysis and log receipt date to track remaining shelf life.

No. Once SS-31 is reconstituted with bacteriostatic water, it must remain refrigerated at 2–8°C and cannot be refrozen. Freezing reconstituted peptide causes ice crystal formation that disrupts peptide tertiary structure and creates aggregates that won’t dissolve upon thawing. The standard protocol is to aliquot reconstituted SS-31 into single-use volumes, freeze those aliquots at −80°C immediately, and thaw each aliquot only once before use. This preserves peptide integrity while allowing flexible dosing schedules.

For lyophilized SS-31, any sustained exposure above 0°C for more than four hours likely degrades potency enough to invalidate the batch — though some suppliers specify tighter limits like −15°C maximum. For reconstituted peptide, storage above 10°C for more than two hours compromises sterility and accelerates degradation. The issue isn’t just temperature magnitude but duration: a brief excursion to 15°C during transfer is less damaging than 12 hours at 5°C, because bacterial growth and peptide hydrolysis are time-dependent processes.

Implementation costs range from $200 for a basic paper logbook system with manual temperature checks to $50,000+ for full LIMS integration with automated environmental monitoring. Most academic labs use a hybrid approach costing $500–2,000: wireless temperature sensors with cloud logging for freezers and refrigerators ($300–800), plus digital spreadsheet templates with automatic timestamps ($0–500), plus printed chain-of-custody forms ($100–200). The cost-benefit calculation favors automated systems for multi-year studies or regulated research where audit failures are expensive.

If your research will support an investigational new drug application, FDA Good Laboratory Practice standards (21 CFR Part 58) require written records demonstrating test article identity, strength, purity, and stability throughout the study. This mandates certificate of analysis retention, storage condition logs with temperature verification, and chain-of-custody records for all transfers. Academic research not intended for regulatory submission has more flexibility, but peer-reviewed journals increasingly require detailed methodology sections that implicitly demand the same documentation rigor.

SS-31 requires more stringent documentation than standard peptides like BPC-157 or thymosin beta-4 because its mitochondrial-targeting mechanism depends on preserving a specific aromatic-cationic motif that degrades readily under suboptimal conditions. Peptides with simpler structures or delivered at higher doses tolerate more handling variability. SS-31’s narrow therapeutic window — effective concentrations often range only 10-fold from threshold to maximum — means small potency losses from storage errors can shift results from significant to null.

Every entry must include: date and time (with time zone if multi-site study), peptide lot number, action taken (received, stored, reconstituted, aliquoted, administered, discarded), storage location with measured temperature, volume or mass handled, personnel initials, and any deviations from protocol with corrective action. For reconstitution specifically, add diluent type and volume, final concentration, pH measurement, and calculated expiration date (28 days post-mixing). These data points let you trace any result back to specific handling conditions.

Light exposure, particularly UV and blue wavelengths, accelerates oxidation of SS-31’s aromatic residues and can reduce potency by 8–12% after eight hours under standard lab fluorescent lighting. If exposure was brief (under 30 minutes during handling), log the incident and continue use with a note flagging potential reduced activity. If vials were left under direct light for multiple hours or days, the conservative approach is to discard the batch and implement light-protective measures (amber vials, foil wrapping, reduced ambient lighting) for replacement stock.

Yes, with modifications for peptide-specific stability parameters. The core structure — receipt logging, storage temperature tracking, reconstitution documentation, deviation records — applies universally to research-grade peptides. What changes are the acceptable temperature ranges, reconstitution protocols, and stability windows. For example, lyophilized [BPC-157](https://www.realpeptides.co/products/bpc-157/) tolerates room temperature storage better than SS-31, while [Cerebrolysin](https://www.realpeptides.co/products/cerebrolysin/) requires different reconstitution protocols. Adapt the template’s specific parameters but maintain the same documentation rigor across your entire peptide inventory.

Failure to log reconstitution timestamps is the most frequent gap, followed closely by inadequate temperature deviation documentation. Researchers often remember to log storage temperatures but skip recording the exact moment peptide was mixed with diluent — which means they can’t verify the 28-day sterility window. This becomes critical during audits or when trying to troubleshoot unexpected results months later. Implementing a ‘no reconstitution without immediate logging’ rule eliminates this gap entirely.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA